Targeted therapies for non-small cell lung cancer: an evolving landscape.
about
Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancerSingle nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancerFUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression dataEfficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristicsLung cancer therapeutics that target signaling pathways: an update.mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survivalEpigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis.Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.Targeted therapies for lung cancer: clinical experience and novel agentsA cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicinEfficacy and safety of angiogenesis inhibitors in small-cell lung cancerPIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitorsMolecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.Roles of the Hippo pathway in lung development and tumorigenesis.Advances in use of immunomodulatory agents--a rheumatology perspective.Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma.Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549.Human positive coactivator 4 is a potential novel therapeutic target in non-small cell lung cancer.Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?Second German-Catalan workshop on epigenetics & cancer.[Detection and evaluation of EGFR mutation status in serum of patients with advanced non-small cell lung cancer treated with EGFR-TKIs].Gene Therapy for Lung Cancer.Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest.
P2860
Q24324198-61D69A20-7CCF-4D9A-AF76-C67CAC867B89Q28816916-7788FB06-37FB-4FC6-BAD8-E85123ACD494Q30711138-4AC20E6E-9FA8-4147-891C-1E168237213FQ33418555-61247A51-9752-4FAD-BB0F-2743C87CBA64Q33817062-65211209-6484-4B95-BB0B-B5B90CD8A04BQ34221272-05BA4E9C-C77B-4C68-935D-618DFCFC8BD0Q34541960-73B55257-329C-402E-8594-B74B3A169262Q34673900-AF4FDFAD-B175-4C99-94A3-E6DB1C66798AQ34704781-8F82EE59-B2CC-477C-9A52-D94D2110C0B1Q35144956-FD5D59F8-9510-4FC4-9FE7-77BD1F8719E4Q35422300-E9BD2FA8-7DA1-4937-89D6-E59121117804Q35824117-12F5106C-D988-4589-BACD-AD497ECDCB23Q35852265-809C22FD-00C3-4AA5-9F1C-271A21108334Q36054970-AB39B96E-F4AE-489C-833E-142C024C079AQ36113044-7B72DB0A-3D9D-47AD-A0F7-94CBB49C1625Q36207113-5D3E9948-0741-4568-9866-42FD44575786Q36207730-5C7BC552-5C8E-4989-B695-A1E5804D969BQ36245945-91B639C3-3A5C-485B-A042-52A882F6317AQ36498832-8495B484-4AAD-40C1-89F0-1FC2E066BBD1Q36653584-B11EEC35-CE58-4B6C-9ABB-6D5C7CA6F79CQ38341378-AE8BE41D-82F2-4C01-AB68-DBE740B21F5EQ38431512-4E545A01-0CF9-4885-8D62-B24A35C69B2EQ38752350-6653ADB3-DA5A-47C2-B9C7-A86A9E9F329FQ39185508-8788171E-74EF-442F-ABE8-A175C9D2C836Q39291884-A4AA1B26-323D-4401-890A-DACDF30E6BFEQ39441334-7B3D28B9-F29C-4E1A-84D7-5CABF66F862FQ42601540-CA95948F-9D37-4F04-8236-35F7CB061947Q45281573-07868A80-F9E1-4512-869E-A2FA875F18B2Q51601238-510389C1-5F1A-4DF8-BA0A-BE2B5A6C8379Q52857191-279212CD-AE85-4FFF-A2C5-1CA987D93B6DQ54403606-F2F2DE9F-10DE-4CF3-B55B-38733E2A6712Q54978331-9490AC1B-C7E9-46AD-AB06-6728E29F8EAB
P2860
Targeted therapies for non-small cell lung cancer: an evolving landscape.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@ast
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@en
type
label
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@ast
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@en
prefLabel
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@ast
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@en
P2860
P1476
Targeted therapies for non-small cell lung cancer: an evolving landscape.
@en
P2093
Robert A Figlin
Sumanta Kumar Pal
P2860
P304
P356
10.1158/1535-7163.MCT-10-0239
P577
2010-06-22T00:00:00Z